National strategy for the integration of pharmacovigilance in the Moroccan TB Control Program
- PMID: 28451026
- PMCID: PMC5398877
- DOI: 10.11604/pamj.2017.26.48.7394
National strategy for the integration of pharmacovigilance in the Moroccan TB Control Program
Abstract
The objective of this work is to demonstrate the interest of integration of pharmacovigilance in Moroccan Tuberculosis Control Program (MTCP). The integration of pharmacovigilance in MTCP was conducted in October 2012with the Global Fund support. We compared the reports notified before and after this integration (period 1: January 2010-October2012; period 2: October 2012-December 2013). The detection of signals was based on the Information Component available inVigiMine. We used the SPSS version 10.0 and Med Calc version 7.3 for data analysis. The average number of spontaneous reports increased from 3.6 to 37.4 cases/month (P< 10-3). The average age was 40.7 ± 17.5 years; the sex ratio was 0.8. Hepatic reactions (32.7%) predominated during the first period, while skin reactions (24.1%) were in the second period (P = 10-4), and40.9% of cases in the first period were serious against 15.8% in second period (P = 0.003). Nine signals were generated (hepaticenzyme increase, cholestasis, jaundice, arthralgia, acne, lower limb edema, pruritus, skin rashes, and vomiting). The integration of pharmacovigilance in Moroccan Tuberculosis Control Program improved the management of ADRs and detected new signals of antituberculosis drugs.
Keywords: Pharmacovigilance; adverse drug reactions; antituberculosis drugs.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
-
- The safety of medicines in public health programmes:pharmacovigilance an essential tool. WHO; 2006. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharma....
-
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients: a meta-analysis of prospective studies. Journal of the AmericanMedical Association. 1998 Apr 15;279(15):1200–5. - PubMed
-
- Safety monitoring of medicinal products- WHO Guidelines for setting up andrunning a pharmacovigilance centre. Stora Torget 3, Uppsala, Sweden: The Uppsala Monitoring Centre; 2000.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical